Based on Stanford research, Surrozen is working on regenerative treatments for a wide range of conditions, with a first focus on liver disease.
Surrozen, a US-based biopharmaceutical spinout of Stanford University, has closed a $50m series B round that included Hartford Healthcare Endowment, the health system’s endowment arm.
Horizons Ventures, NS Investment and Column Group also participated in the round, as did several new and existing backers that were not identified.
Anna Berkenblit, senior vice-president and chief medical officer at biotechnology firm Immunogen, joined Surrozen’s board of directors in conjunction with the round but it is unclear whether the corporate invested…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
